Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo Prioritizes R&D On Thrombosis And Three Other Areas

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo unveiled a new business strategy at an Oct. 8 conference in Tokyo. The strategy includes prioritizing research and development resources to antibody drug denosumab and CS-8635, a three-drug combination hypertension treatment. The company has identified four research areas as growth engines to focus R&D resources: thrombosis, cancer, diabetes and arthritis. In the thrombosis area, the company plans to focus on antiplalelet and anticlotting drugs. Oral anti-Xa drug DU-176b has completed Phase II trials in Japan, Europe and the U.S., and international joint Phase III trials will start in November. At the meeting, Daiichi Sankyo also disclosed the company's decision to halt developing antiplatelet drug DZ-697b. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts